Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy
DOI: https://doi.org/10.2147/IJN.S404848
IF: 7.033
2023-03-16
International Journal of Nanomedicine
Abstract:Zhi-Xin Zhong, 1, &ast Xu-Zhao Li, 1, &ast Jin-Tao Liu, 1 Nan Qin, 1 Hong-Quan Duan, 1– 3 Xiao-Chuan Duan 1, 4 1 School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China; 2 Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, People's Republic of China; 3 Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, 300070, People's Republic of China; 4 School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, 300070, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hong-Quan Duan; Xiao-Chuan Duan, School of Pharmacy, School of Biomedical Engineering and Technology, Tianjin Medical University, 22, Qi Xiang Tai Road, Tianjin, 300070, People's Republic of China, Tel +86-22-83336680, Fax +86-22-83336560, Email ; Purpose: Chemotherapy is a significant and effective therapeutic strategy that is frequently utilized in the treatment of cancer. Small molecular prodrug-based nanoassemblies (SMPDNAs) combine the benefits of both prodrugs and nanomedicine into a single nanoassembly with high drug loading, increased stability, and improved biocompatibility. Methods: In this study, a disulfide bond inserted 7-ethyl-10-hydroxycamptothecin (SN38) prodrug was rationally designed and then used to prepare nanoassemblies (SNSS NAs) that were selectively activated by rich glutathione (GSH) in the tumor site. The characterization of SNSS NAs and the in vitro and in vivo evaluation of their antitumor effect on a pancreatic cancer model were performed. Results: In vitro findings demonstrated that SNSS NAs exhibited GSH-induced SN38 release and cytotoxicity. SNSS NAs have demonstrated a passive targeting effect on tumor tissues, a superior antitumor effect compared to irinotecan (CPT-11), and satisfactory biocompatibility with double dosage treatment. Conclusion: The SNSS NAs developed in this study provide a new method for the preparation of SN38-based nano-delivery systems with improved antitumor effect and biosafety. Graphical Keywords: 7-ethyl-10-hydroxycamptothecin, prodrug, nanoassemblies, glutathione responsive, pancreatic cancer therapy According to the GLOBOCAN database, there have been an estimated 19.3 million new cancer cases and nearly 10 million cancer deaths in 2020, and the global cancer burden is predicted to reach 28.4 million cases in 2040, a 47% increase from 2020. 1 Surgery, radiation therapy, and systemic therapy including chemotherapy, targeted therapy, hormonal therapy, and immunotherapy are reported as cancer treatment modalities. 2 Among them, chemotherapy is a crucial therapeutic approach and has been used extensively for the treatment of cancer. 3 The treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited. The majority of patients diagnosed with advanced disease are ineligible for surgical treatment. In addition, the progression of pancreatic cancer to an advanced stage is characterized by a rapid decline in clinical status, so chemotherapy remained the first-line treatment. 4 In clinical trials, the topoisomerase inhibitor irinotecan (CPT-11) was highly recommended for the treatment of various kinds of solid tumors. 5 However, CPT-11 has not been successfully implemented as a second-line pancreatic cancer therapy. 6 This was primarily due to the insufficient conversion ratio (2–8%) of CPT-11 to its active metabolite 7-ethyl-10-hydroxycamptothecin (SN38) by carboxylesterase (CE) on the body. 7 It has been reported that SN38 is 100–1000 times more potent than CPT-11, which has been considered a potential anticancer agent. However, because of its poor solubility (11–38 μg/mL in water), instability (inactive at pH 7.4), and dose-limiting side effects (myelosuppression and diarrhea), its applications as an anticancer drug were severely limited. 8,9 As a result, the development of effective SN38-drug delivery systems has significant clinical implications. The delivery of therapeutic agents using a nanoparticulate drug delivery system (nano-DDS) has been thoroughly studied. 10,11 Several nano-DDS have been investigated in clinical trials for SN38. For example, SN38 conjugates such as NK012 (a SN38 and PEG-PLGA conjugate) and EZN-2208 (a poly (ethylene glycol) and SN38 conjugate). In addition, liposomal formulations, such as liposome-encapsulated SN38 (LE-SN38) and liposomal irinotecan (Onivyde®), have been developed. 6,12–14 In the Phase III -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology